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Multiple sclerosis (MS) is an immune-mediated disorder; however, little is known about the triggering factors of the abnormal
immune response. Diﬀerent viruses from the herpes family have been mentioned as potential participants. Here, we review
the evidences that support the association of varicella zoster virus (VZV) with MS. Epidemiological studies from geographical
areas, where incidence of MS has increased in recent decades, pointed out a high frequency of varicella and zoster in the clinical
antecedents of MS patients, and also laboratory investigations have found large quantities of DNA from VZV in leucocytes and
cerebrospinal ﬂuid of MS patients restricted to the ephemeral period of MS relapse, followed by disappearance of the virus during
remission. The above observations and the peculiar features of VZV, mainly characterized by its neurotropism and long periods of
latency followed by viral reactivation, support the idea on the participation of VZV in the etiology of MS. However, as with reports
from studies with other viruses, particularly Epstein Barr virus, conﬂicting results on conﬁrmatory studies about the presence of
viralgeneproductsinbraintissueindicatetheneedforfurtherresearchonthepotentialparticipationofVZVintheetiologyofMS.
1.Introduction
Several human pathogenic viruses have been, at one time or
another, implicated as potential participants in the etiology
of MS. Since the early 60s of the last century some studies
indicated that, according to the clinical picture and the
histopathological characteristics of MS lesions, a viral agent
could be responsible for the disease [1]. Serological analysis
of antiviral antibodies gave support to this hypothesis;
in this way, some results suggested that viruses from the
herpes family as well as other viruses from exanthematic
diseases of childhood might be potential candidates [1–3].
However,mostinitialreportsfrompositivestudiesdisclosing
viral DNA or antiviral antibodies could not be conﬁrmed
in subsequent investigations and were followed either by
controversy or by novel results pointing out another viral
candidate [4]. These failed attempts have been a common
story for the last ﬁfty years. It could be said that MS
has been, over the decades, among the human diseases
withmostclaimspostulatingetiologicalcandidates;however,
most corroborative studies have failed to replicate initial
observations [2].
2. Autoimmunity versusViralInfectioninthe
Etiology of MS
Two main hypotheses have been constructed to explain the
pathophysiology of MS: one is autoimmunity, the other an
infectious agent, most probably a virus. In favor of the
former a legion of studies has demonstrated the peculiar
activation of the immune response during exacerbations of
the disease. As the myelin is a highly antigenic structure
capable of inciting an autoimmune response, it seems logical
to postulate that MS might belong to the large group
of autoimmune disorders. Although MS is obviously an
immune-mediated disorder, some relevant obstacles exist
to consider MS as a classical autoimmune disorder; among
them is the lack of a replicative model of MS in experimental
animals.Thismodel,whichshouldbeidenticaltothehuman
disease would result from the injection in healthy animals2 Multiple Sclerosis International
of the autologous antigen responsible for the autoimmune
response, this requisite has been fulﬁlled in the case of other
well-characterized autoimmune disorders of the nervous
system like myasthenia gravis, experimental encephalitis
(a model for post-vaccine encephalitis), and experimental
polyneuritis (a model for Guillain-Barr´ e Syndrome), but in
the case of MS the absence of “experimental MS” has been
replaced by “similar” but not identical experimental models
[5, 6]. Another major obstacle to consider MS as a typical
autoimmune disorder is the impossibility to transfer the
disease from one aﬀected individual to a healthy other by the
injection of immune mediators such as immunoglobulins or
immune cells, such as the case of disorders like myasthenia
gravis or experimental encephalitis, where the injection
either of IgG or T cells from a sick host to an unaﬀected
one can translate temporarily the histopathological features
of the disease. Additional evidence that challenges the
autoimmune hypothesis of MS comes from recent reports
that show the primary involvement of neural cells from
grey matter and axons in the pathogenesis of MS in which
axonal transection and neural injury are clearly evident in
areas with normal-appearing white matter; these lesions in
gray matter correlate with disabilities more strongly than
white matter atrophy [7]. The primary lesions of neural
cells rather than the unique participation of myelin antigens
argues against the autoimmune hypothesis. Finally, the fact
that the immune response is activated in restricted areas
or plaques of the white matter, leaving unaﬀected many
other sites containing the same myelin protein, is diﬃcult to
explain on the basis of an autoimmune etiology; if MS was of
autoimmune origin, the same myelin protein everywhere in
the brain would be involved and recognized by the immune
activation; this is not the case in MS, where the immune-
mediated lesion takes place within precise limiting borders
amid an extensively myelinated zone, leaving unharmed
neighboring areas [8].
In contrast with autoimmunity in the etiology of the
disease the viral hypothesis would be more coherent with
thepathophysiologicalprocessofMS;thesegmentarylesions
and the relapse-remission cycles do favor the idea of an
infectious agent, most probably a virus involved as a trig-
gering element of the immune reaction [9–11]. However, in
comparison with the large body of evidence on the immune
participation in the pathogenesis of MS the potential viral
agent as the etiological cue has remained elusive [12].
In between the two possible etiologies of MS, autoim-
munity and infection, the subject of genetic susceptibility
has been explored recently with novel molecular techniques
which have disclosed complicated genetic traits associated
with MS [13–17].
3.VaricellaZoster Virusand MultipleSclerosis
Herpes viruses hold very intriguing properties, among them
is the capacity to remain latent in their host for long periods,
evendecades,andtheirability toinduce recurrentinfections.
Some herpes viruses are neurotrophic, particularly those
from the subgroup alpha-herpes viruses, like herpes simplex
virus and, most remarkably, varicella zoster virus (VZV)
[18]. By means of the above properties these viruses remain
within the nervous system from their hosts for decades
producing periodic exacerbations; in the case of herpes
simplex 1 the typical labial blisters, in the case of VZV the
initial infection as chickenpox during childhood and late
reactivations as zoster in older individuals.
Although VZV has been postulated as a possible can-
didate to participate in MS [19–21], the results of most
epidemiological or serological studies failed to conﬁrm this
link leaving uncertain the participation of VZV in the
etiology of MS; a report evaluating 40 studies in the period
1965–1999 indicated that there is insuﬃcient evidence to
support the association of MS with VZV or zoster infections
[22]. However, recent studies done in our laboratory began
with the observation that the incidence of MS in Mexico
was having a progressive increase, from a very rare disease
in the 70s to a very frequent one nowadays, as seen by the
growing incidence frequency of new cases in neurological
wards throughout the country [23, 24]. If this was the
case, the study of MS in Mexican patients represents a
unique opportunity to search for the possible emergence of
epidemiological factors related to the increase of exposure to
novel environmental circumstances related with the etiology
of MS. The initial hypothesis tested in MS patients was
related to nutritional factors that have drastically changed
during the past thirty years (adoption of foreign fast-food
diets,changesintheschemeoftraditionaldiets,introduction
of industrialized foods) together with the investigation of
individual exposure to factors that have been postulated
as potential risks for MS such as personal pets, childhood
infections, and previous allergies. Our results from that
investigation pointed out as a sole highly signiﬁcant risk
factor for MS the antecedent of varicella during childhood
[25, 26]. It seems important to stress the fact that this
antecedent could only be uncovered in geographical areas
where chickenpox is not a highly frequent disease of children
[27, 28]. In this sense, global epidemiological studies have
indicated that varicella is almost universal in cold and
temperate countries from the northern hemisphere, whereas
its incidence decreases drastically in tropical countries below
the parallel 40, where Mexico is located [29]; in these areas
theincidenceofvaricelladuringinfancyisaboutﬁftypercent
or lower. Coincidentally, the epidemiology of MS is similar
to that of varicella, high in the northern hemisphere sharply
decreasing towards tropical areas [30]. Our initial study
demonstrated that the antecedent of varicella in MS patients
was far more frequent than that in matched controls and in
the general population [25, 31]; moreover, the mean age of
infection in MS patients (8 years of age) was signiﬁcantly
older than in controls (5 years of age). The above unexpected
ﬁndings prompted us to study the possible presence of
VZV in MS patients: the initial study searched for DNA
from VZV in peripheral mononuclear blood cells (PBMC)
from 82 MS patients [32]; results showed that only 13
(16%) were positive by polymerase chain reaction (PCR)
to one or various genes speciﬁc for VZV. However, when
reviewing retrospectively the clinical charts from the few
positive cases, to our surprise in all of them the blood
samples had been taken within the ﬁrst week of an acuteMultiple Sclerosis International 3
relapse of MS, from this cohort only 2 patients with this
particular condition were negative; thus, 11 MS patients
studied during relapse (82%) were positive for VZV DNA.
In contrast, all MS patients who were on remission at the
time of the test were negative [32]. With these ﬁndings
we hypothesized that the presence of VZV-DNA in PBMC,
restricted to the initial days of an acute relapse, could signify
either an epiphenomenon of virus reactivation due to the
immune disturbances classically associated with episodes of
MS exacerbation or that the VZV was primary involved in
the etiopathogenesis of MS [32]. Subsequent studies have
indicated that the latter explanation is indeed more feasible
than the former. When PBMC from neurological patients
with inﬂammatory, tumoral, or autoimmune ailments, as
well as immunosuppressed patients were tested for VZV
antigens, the results were all negative, identically to those
obtained in healthy controls [33], thus showing that the
abnormal activation or suppression of the immune response
is not commonly associated with an epiphenomenon of VZV
activation. It was also observed by real/time PCR that the
amount of VZV found in PBMC from MS patients during
relapse was high during the ﬁrst week of the acute relapse
but became gradually minor on clinical remission, until
its disappearance in samples taken 2 months later [32–34].
These variations were observed in patients studied at various
times during the cycle remission/relapse of MS. In these
studies no similar phenomenon was seen when other herpes
virusesweresearchedsuchasherpessimplex1and2,Epstein
Barr virus, human herpes virus 6, and cytomegalovirus [33,
35].
Theaboveresultsstrengthenedtheideaofadirectpartic-
ipation of VZV in the etiology of MS [36], not necessarily as
casualinfectionbutalsopossibly throughhost-viralimmune
interactions [37] which was corroborated in an additional
studyaimedtosearchfortheviruswithinthecentralnervous
system; the amount of viral particles from patients during
relapse were measured simultaneously in PBMC and in CSF
[38]. The amount of viral DNA measured in MS patients
during relapse was hundreds of times higher in CSF than
that in PBMC; in both locations, the amount decreased,
as previously observed, after the acute relapse. Even more
relevant, viral particles identical to VZV were observed by
electron microscopy in the CSF from all 15 MS cases studied
in relapse, these viral particles were precipitated with anti-
VZV antibodies [38, 39]. Similar to the ﬁndings by PCR, the
viral particles could not be observed in the CSF from the
same MS patients when studied during remission [38].
4. Possible Pathway of VZV Infection in MS
VZV has the ability to remain latent in its host for long
periods, which may extend several decades. If a subject
suﬀers from varicella at 4 years of age and herpes zoster at 84
years of age, the virus remained viable, but in latency for an
astonishing 80 years it is apparent that no other known viral
disease infection reaches these extremes of latency, of which
we know so little. From studies with subjects infected with
HIV we already know that the same viral strain that caused
thediseaseduringchildhoodistheonethatcausesthedisease
in the elderly, giving support to the idea of a true lasting
latency, rather than two episodes caused by nonrelated
isolated infections separated by a very long period [18]. Also,
the fact that both, varicella and zoster, are totally diﬀerent
diseasescausedbythesameinfectiousagentisintriguingand
gives support to the concept of multiple viral pathogenicity
[40], where the same virus can produce various diseases
according to the age and susceptibility of the subject. Thus,
it might be postulated that VZV produces varicella, a
systemic disease at early ages of the host; it also produces
zoster, a local disease of the peripheral nervous system in
the elderly, and we speculate, based on our ﬁndings, that
it could also produce MS, a local disease of the central
nervous system during adulthood. In the case of varicella the
viral disease behaves as a highly infectious and contagious
infection associated with low pathogenicity [28], whereas in
the case of zoster and MS it behaves as a local infection
either of the peripheral or the central nervous system,
the former as a centrifugal and the latter as a centripetal
spread, from the neural ganglia hosting the latent virus; the
development of these disorders would largely depend on
individual susceptibility within the still enigmatic process
of viral latency and reactivation [9, 41]. The hypothetical
etiological mechanism of VZV infection in MS could be the
suddenactivationofalatentVZVintheneuralgangliawhich
wouldspreadto the centralnervous system,perhapsthrough
the ependymal cells, gaining access to the brain or the spinal
cordviatheventriclesandthecentralcanal.Theusuallesions
located mostly in periventricular areas, as seen on imaging
studies from MS patients, support this idea.
Although various herpes viruses have been implicated
as participants in the etiology of MS, the most cited by
current studies are human herpes virus 6 and Epstein Barr
virus [2, 12, 42]. However, these two candidates have been
challenged by other investigations [35, 43]. In our studies,
ﬁndings of DNA from these two viruses in MS patients
were not diﬀerent from controls; also, particularly during
exacerbations of MS the results were not diﬀerent from those
obtained during remission. The participation of VZV in
the etiopathogenesis of MS still has to be corroborated by
additional studies; so far, two investigations have conﬁrmed
our initial reports [32, 33, 38] on the presence of VZV in
MS [44, 45]; in contrast, Burgoon et al. failed to show the
presence of VZV virions or DNA in the CSF or in the acute
plaques of MS patients, whereas recombinant antibodies
prepared from clonally expanded plasma cells in MS CSF,
which are thought to represent the intrathecally synthesized
oligoclonal IgG, did not bind to VZV-infected cells [46].
Nevertheless, recent results from our laboratory have also
documented the presence of VZV DNA in progressive forms
of MS but in minor quantity from that found in CSF
or in blood samples taken during MS relapse in patients
with the relapse/remission form of MS [47]. Similar to
these controversial results on VZV, in the case of EBV,
anotherherpesvirusthathasbeenimplicatedbymanyrecent
reports as potential participant in the etiology of MS [48–
52], various studies have failed to replicate initial results
[53–57], but it has been demonstrated that a history of
infectious mononucleosis is associated with an increased risk4 Multiple Sclerosis International
to develop MS [58]. These arguments on viral candidates
possibly implicated in the etiology of MS indicate the need
for original investigative approaches either to conﬁrm or to
discard deﬁnitively the participation of these or any other
virus in the etiopathogenesis of MS.
If VZV has a relevant role in the etiology of MS, several
questions, related to individual genetic susceptibility and to
the mechanisms of viral latency and reactivation of VZV
from the dorsal root ganglia towards the CNS, are interesting
challenges for future research.
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